Professor Mark Boyd
Professor Boyd is an internationally recognised infectious disease expert. He has led project teams in HIV research in Thailand, as well as at the Kirby Institute for infection and immunity at the University of New South Wales. He has had a key role in two major, multicentre, international randomised clinical trials (‘SECOND-LINE’ and ‘Encore1’) sponsored by the Kirby Institute, which have brought changes to the WHO guidelines on the antiretroviral management of HIV infection in adults and adolescents.
Until recently Professor Boyd was an Associate Professor at the Kirby Institute, a consultant physician in HIV Medicine and Infectious Diseases and a Visiting Medical Officer in inner Sydney as well as regional NSW.
Research
In 2014 he was awarded the Frank Fenner Award for Advanced Research in Infectious Diseases by the Australasian Society for Infectious Diseases. He has published more than 100 papers, book chapters, reviews and commentaries and been an investigator on grants worth in excess of $17 million.
“I am a great believer in the conduct of research that aims to make a clear and positive difference in peoples’ lives,” Professor Boyd says. “High quality clinical research and the rapid translation of robust research findings into clinical practice is key to driving improvements in patient outcomes and public health. I am delighted to have been offered this unique position at the Lyell McEwin, where I aim to combine academic rigour with a commitment to the highest quality service delivery to the population of the NAHLN.”
Appointments
| Date | Position | Institution name |
|---|---|---|
| 2015 - 2016 | Visiting Medical Officer | Murrumbidgee Health District |
| 2015 - 2016 | Visiting Medical Officer | Albury Wodonga Health District |
| 2013 - 2016 | Associate Professor | University of New South Wales |
| 2007 - 2012 | Clinical Project Leader | St Vincent's Hospital |
| 2004 - 2007 | Senior Consultant in Infectious Diseases and Microbiology | Flinders Medical Centre |
| 2000 - 2004 | Clinical Project Leader | HIV Netherlands Australia Thailand Research Collaboration |
Awards and Achievements
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2014 | Award | The Frank Fenner Award for Advanced Research in Infectious Diseases | Australasian Society for Infectious Diseases (ASID) Inc. | — | — |
| 2014 | Award | Outstanding Reviewer for 2013 | — | — | — |
| 1986 | Award | The Alfred Houston Senior Prize in Philosophy | University of Tasmania | — | — |
Education
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2006 | Flinders University | Australia | (MHID) - Master of Health and International Development |
| 2001 - 2006 | University of New South Wales | Australia | MD - Doctor of Medicine |
| 1997 | University of Alabama (USA) and Universidad Peruana Cayetano-Heredia (Perú) | Peru and United States | DCTM&H - Dip. In Clinical. Trop. Med. and Hygiene |
| 1987 - 1992 | Flinders University | Australia | BM, BS Medicine, Surgery |
| 1983 - 1986 | University of Tasmania | Australia | BA Philosophy - English Literature |
Certifications
| Date | Title | Institution name | Country |
|---|---|---|---|
| 2013 | Graduate Certificate in University Learning and Te | University of New South Wales | Australia |
| 2011 | Certificate for Ethics Training for Human Research | Monash University | Australia |
| 1995 | Fellowship | Royal Australasian College of Physicians | Australia |
Research Interests
Journals
| Year | Citation |
|---|---|
| 2018 | Yao, A., Moore, C., Lim, P., Molina, J. -M., Madero, J., Kerr, S., . . . Boyd, M. (2018). Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.. Antiviral therapy, 23(1), 21-32. DOI |
| 2018 | Boyd, M., Cooper, D., & Gilks, C. (2018). Towards a universal second-line fixed-dose combination ART. The Lancet HIV, 5(1), e3-e5. DOI Scopus2 Europe PMC2 |
| 2018 | Stockdale, A., Saunders, M., Boyd, M., Bonnett, L., Johnston, V., Wandeler, G., . . . Geretti, A. (2018). Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66(12), 1846-1857. DOI |
| 2018 | Boyd, M., & Cooper, D. (2018). Combination ART: are two drugs as good as three?. The Lancet, 391(10123), 817-819. DOI |
| 2018 | Mwasakifwa, G., Moore, C., Carey, D., Amin, J., Penteado, P., Losso, M., . . . Boyd, M. (2018). Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS, 32(3), 357-361. DOI |
| 2017 | Petoumenos, K., Choi, J., Hoy, J., Kiertiburanakul, S., Ng, O., Boyd, M., . . . Law, M. (2017). CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antiviral Therapy, 22(8), 659-668. DOI |
| 2017 | Boyd, M., Mocroft, A., Ryom, L., d'Arminio Monforte, A., Sabin, C., El-Sadr, W., . . . Law, M. (2017). Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D:A:D observational study. PLoS Medicine, 14(11), e1002424-1-e1002424-14. DOI Scopus1 Europe PMC1 |
| 2017 | Bell, S., Mena, G., Dean, J., Boyd, M., Gilks, C., & Gartner, C. (2017). Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes. Drug and Alcohol Dependence, 177, 67-70. DOI |
| 2017 | Lau, A., Kong, F., Fairley, C., Donovan, B., Chen, M., Bradshaw, C., . . . Hocking, J. (2017). Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. BMC Infectious Diseases, 17(1), 35-1-35-9. DOI Scopus2 WoS3 Europe PMC3 |
| 2017 | Aung, N., Hanson, J., Kyi, T., Htet, Z., Cooper, D., Boyd, M., . . . Saw, H. (2017). HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Research and Therapy, 14(1), 1-7. DOI Scopus1 Europe PMC1 |
| 2017 | Rhee, S., Varghese, V., Holmes, S., Van Zyl, G., Steegen, K., Boyd, M., . . . Shafer, R. (2017). Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 18, 225-235. DOI Scopus6 Europe PMC5 |
| 2017 | Boyd, M. (2017). Body composition substudy of the SECOND-LINE study – Author's reply. The Lancet HIV, 4(6), e240. DOI |
| 2017 | Bell, S., Dean, J., Gilks, C., Boyd, M., Fitzgerald, L., Mutch, A., . . . Gartner, C. (2017). Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health, 14(7), 799. DOI Scopus1 Europe PMC1 |
| 2017 | Boyd, M., & Cooper, D. (2017). Long-acting injectable ART: next revolution in HIV?. The Lancet, 390(10101), 1468-1470. DOI Scopus2 Europe PMC2 |
| 2017 | Thit, S., Aung, N., Htet, Z., Boyd, M., Saw, H., Anstey, N., . . . Hanson, J. (2017). The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study. BMC Medicine, 15(1), 145-1-145-11. DOI Scopus1 Europe PMC1 |
| 2017 | Puhr, R., Petoumenos, K., Youds, D., Law, M., Templeton, D., Ellis, D., . . . Bargh, K. (2017). The impact of changes in HIV management guidelines on time to treatment initiation in Australia. HIV Medicine, 18(9), 701-703. DOI Scopus1 |
| 2017 | Boyd, M., Amin, J., Mallon, P., Kumarasamy, N., Lombaard, J., Wood, R., . . . Cooper, D. (2017). Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. The Lancet HIV, 4(1), e13-e20. DOI Scopus4 WoS3 Europe PMC3 |
| 2016 | Zaunders, J., Danta, M., Bailey, M., Mak, G., Marks, K., Seddiki, N., . . . Koelsch, K. (2016). CD4⁺ T follicular helper and IgA⁺ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals. Frontiers in Immunology, 7(OCT), 438. DOI Scopus5 Europe PMC2 |
| 2016 | Boyd, M., Cooper, D., Crock, E., Crooks, L., Giles, M., Grulich, A., . . . Yarwood, T. (2016). Sexual transmission of HIV and the law: An Australian medical consensus statement. Medical Journal of Australia, 205(9), 409-412. DOI |
| 2016 | Winston, A., Stöhr, W., Antinori, A., Arenas-Pinto, A., Llibre, J., Amieva, H., . . . Palmisiano, L. (2016). Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 17(6), 471-478. DOI Scopus3 Europe PMC4 |
| 2016 | Lambert-Niclot, S., George, E., Pozniak, A., White, E., Schwimmer, C., Jessen, H., . . . Aagaard, B. (2016). Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 71(4), 1056-1062. DOI Scopus7 Europe PMC7 |
| 2016 | Boyd, M., & Cooper, D. (2016). Tenofovir alafenamide: safer, but questions remain. The Lancet HIV, 3(4), e148-e149. DOI Scopus1 |
| 2016 | Lam, E., Moore, C., Gotuzzo, E., Nwizu, C., Kamarulzaman, A., Chetchotisakd, P., . . . Boyd, M. (2016). Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study. AIDS Research and Human Retroviruses, 32(9), 841-850. DOI Scopus3 Europe PMC3 |
| 2016 | Achhra, A., Mwasakifwa, G., Amin, J., & Boyd, M. (2016). Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. The Lancet HIV, 3(8), e351-e360. DOI Scopus22 Europe PMC14 |
| 2016 | Alvarez, E., Belloso, W., Boyd, M., Inkaya, A., Hsieh, E., Kambugu, A., . . . Mallon, P. (2016). Which HIV patients should be screened for osteoporosis: An international perspective. Current Opinion in HIV and AIDS, 11(3), 268-276. DOI Scopus4 Europe PMC3 |
| 2016 | Boyd, M., & Cooper, D. (2016). Novel antiretroviral agents and universal access to HIV care. The Lancet HIV, 3(1), e2-e3. DOI |
| 2015 | Boyd, M., Moore, C., Molina, J., Wood, R., Madero, J., Wolff, M., . . . Cooper, D. (2015). Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. The Lancet HIV, 2(2), 42-51. DOI Scopus26 Europe PMC20 |
| 2015 | Cummins, N., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J., . . . Badley, A. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine, 2(7), 706-712. DOI Scopus9 Europe PMC6 |
| 2015 | Boyd, M., Donovan, B., Prestage, G., Chen, M., Petoumenos, K., Gray, R., . . . Klausner, J. (2015). Is it time to rethink syphilis control?. Clinical Infectious Diseases, 60(2), 325-326. DOI Scopus4 Europe PMC3 |
| 2015 | Templeton, D., Wright, S., McManus, H., Lawrence, C., Russell, D., Law, M., . . . Guelfi, G. (2015). Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 15(1), 326. DOI Scopus2 Europe PMC2 |
| 2015 | McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 255. DOI |
| 2015 | Wright, S., Law, M., Cooper, D., Keen, P., McDonald, A., Middleton, M., . . . Roth, N. (2015). Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 18(1), 19463. DOI Scopus4 Europe PMC2 |
| 2015 | McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 131-139. DOI Scopus3 WoS2 |
| 2015 | Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 )). PLoS ONE, 10(10), e0140623. DOI Scopus3 |
| 2015 | Boyd, M., & Cooper, D. (2015). The LATTE study: A provocative brew. The Lancet Infectious Diseases, 15(10), 1116-1117. DOI |
| 2015 | Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802. DOI Scopus37 Europe PMC22 |
| 2015 | Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection. PLoS ONE, 10(2), e0118228. DOI Scopus14 Europe PMC11 |
| 2015 | Han, N., Wright, S., O'Connor, C., Hoy, J., Ponnampalavanar, S., Grotowski, M., . . . Zhang, F. (2015). HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD). HIV Medicine, 16(3), 152-160. DOI Scopus5 Europe PMC3 |
| 2015 | Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., . . . Arribas, J. R. (2015). Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. The Lancet HIV, 2(11), e464-e473. DOI |
| 2015 | Beyrer, C., Birx, D. L., Bekker, L. -G., Barré-Sinoussi, F., Cahn, P., Dybul, M. R., . . . Montaner, J. S. (2015). The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. The Lancet, 386(9993), 505-507. DOI |
| 2014 | Raffi, F., Babiker, A. G., Richert, L., Molina, J. -M., George, E. C., Antinori, A., . . . Pozniak, A. (2014). Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. The Lancet, 384(9958), 1942-1951. DOI |
| 2014 | Haskelberg, H., Pocock, N., Amin, J., Ebeling, P., Emery, S., & Carr, A. (2014). Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(4), e94858-1-e94858-8. DOI |
| 2014 | Haskelberg, H., Cordery, D., Amin, J., Kelleher, A., Cooper, D., & Emery, S. (2014). HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(3), e93333-1-e93333-7. DOI |
| 2014 | McManus, H., Petoumenos, K., Franic, T., Kelly, M., Watson, J., O’Connor, C., . . . Law, M. (2014). Determinants of Suicide and Accidental or Violent Death in the Australian HIV Observational Database. PLoS ONE, 9(2), e89089. DOI |
| 2014 | McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. (2014). Loss to follow-up in the Australian HIV Observational Database. Antiviral Therapy, 20(7), 731-741. DOI |
| 2014 | Achhra, A., Boyd, M., Law, M., Matthews, G., Kelleher, A., & Cooper, D. (2014). Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial. PLoS ONE, 9(6), e99530. DOI Scopus3 Europe PMC2 |
| 2014 | Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482. DOI Scopus75 Europe PMC59 |
| 2014 | Wright, S., Hoy, J., Mulhall, B., O'connor, C., Petoumenos, K., Read, T., . . . Boyd, M. (2014). Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 66(1), 55-64. DOI Scopus10 WoS7 Europe PMC8 |
| 2014 | Holt, S., Gracey, D., Levy, M., Mudge, D., Irish, A., Walker, R., . . . Boyd, M. (2014). A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 11(1), 35-1-35-10. DOI Scopus4 WoS4 Europe PMC3 |
| 2014 | Revell, A., Boyd, M., Wang, D., Emery, S., Gazzard, B., Reiss, P., . . . Larder, B. (2014). A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 15(7), 442-448. DOI Scopus2 |
| 2014 | Haskelberg, H., Mallon, P., Hoy, J., Amin, J., Moore, C., Phanuphak, P., . . . Emery, S. (2014). Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. Journal of Acquired Immune Deficiency Syndromes, 67(2), 161-168. DOI Scopus12 Europe PMC11 |
| 2013 | Wright, S., Boyd, M., Yunihastuti, E., Law, M., Sirisanthana, T., Hoy, J., . . . Petoumenos, K. (2013). Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS ONE, 8(6), e64902-1-e64902-12. DOI Scopus12 WoS8 Europe PMC11 |
| 2013 | Achhra, A., & Boyd, M. (2013). Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature. AIDS Research and Therapy, 10(1), 33. DOI Scopus20 Europe PMC14 |
| 2013 | Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Second-line study team. (2013). HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One, 8(10), e77138-1-e77138-9. DOI Scopus11 WoS9 Europe PMC8 |
| 2013 | Boyd, M., & Cooper, D. (2013). SPRING-2 the future of antiretroviral therapy. The Lancet Infectious Diseases, 13(11), 908-909. DOI Scopus4 Europe PMC3 |
| 2013 | Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Boyd, M. (2013). Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS, 27(15), 2403-2411. DOI Scopus24 WoS27 Europe PMC20 |
| 2013 | Boyd, M., & Donovan, B. (2013). Antiretroviral therapy: Dolutegravir sets SAIL(ING). The Lancet, 382(9893), 664-666. DOI Scopus2 |
| 2013 | Schneider, K., Nwizu, C., Kaplan, R., Anderson, J., Wilson, D., Emery, S., . . . Boyd, M. (2013). The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE, 8(2), e54435. DOI Scopus1 Europe PMC1 |
| 2013 | Byakwaga, H., Petoumenos, K., Ananworanich, J., Zhang, F., Boyd, M., Sirisanthana, T., . . . Emery, S. (2013). Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database. Journal of the International Association of Providers of AIDS Care, 12(4), 270-277. DOI Scopus3 Europe PMC2 |
| 2013 | Jansson, J., Wilson, D., Carr, A., Petoumenos, K., & Boyd, M. (2013). Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS, 27(8), 1245-1251. DOI Scopus10 Europe PMC8 |
| 2013 | Boyd, M. (2013). Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. The Lancet, 381(9883), 2091-2099. DOI Scopus96 Europe PMC66 |
| 2013 | Wright, S., Petoumenos, K., Boyd, M., Carr, A., Downing, S., O'Connor, C., . . . Law, M. (2013). Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Medicine, 14(4), 208-216. DOI Scopus12 Europe PMC9 |
| 2013 | Petoumenos, K., van Leuwen, M., Vajdic, C., Woolley, I., Chuah, J., Templeton, D., . . . Law, M. (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Medicine, 14(2), 77-84. DOI |
| 2012 | McManus, H., O'Connor, C., Boyd, M., Broom, J., Russell, D., Watson, K., . . . Law, M. (2012). Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE, 7(11), e48839. DOI Scopus35 Europe PMC30 |
| 2012 | Avihingsanon, A., Van Der Lugt, J., Singphore, U., Gorowara, M., Boyd, M., Ananworanich, J., . . . Ruxrungtham, K. (2012). Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study. AIDS Research and Human Retroviruses, 28(10), 1170-1176. DOI Scopus1 |
| 2012 | Boyd, M., & Mohapi, L. (2012). Stretching delivery of HIV health services. The Lancet, 380(9845), 865-867. DOI |
| 2012 | Haskelberg, H., Hoy, J., Amin, J., Ebeling, P., Emery, S., Carr, A., . . . Woolley, I. (2012). Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 7(6), 1-9. DOI Scopus53 Europe PMC44 |
| 2012 | Boyd, M. (2012). Dolutegravir-a promising antiretroviral in development. The Lancet Infectious Diseases, 12(2), 90-91. DOI Scopus7 Europe PMC4 |
| 2012 | Boyd, M., & Cooper, D. (2012). Optimisation of HIV care and service delivery: Doing more with less. The Lancet, 380(9856), 1860-1866. DOI Scopus11 Europe PMC8 |
| 2012 | Carey, D., Pett, S., Bloch, M., Wand, H., MacRae, K., Beileiter, K., . . . Cooper, D. (2012). A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. Journal of Acquired Immune Deficiency Syndromes, 60(2), 143-149. DOI Scopus16 Europe PMC10 |
| 2011 | Byakwaga, H., Kelly, M., Purcell, D., French, M., Amin, J., Lewin, S., . . . Emery, S. (2011). Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4<sup>+</sup>T-cell response: A randomized controlled trial. Journal of Infectious Diseases, 204(10), 1532-1540. DOI Scopus44 WoS41 Europe PMC34 |
| 2011 | Revell, A., Wang, D., Boyd, M., Emery, S., Pozniak, A., De Wolf, F., . . . Larder, B. (2011). The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS, 25(15), 1855-1863. DOI Scopus18 Europe PMC12 |
| 2011 | Martin, A., Amin, J., Emery, S., Baker, D., Carr, A., Cooper, D., & Bloch, M. (2011). Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 6(10), e26885. DOI |
| 2011 | Kowalska, J. D., Friis-Møller, N., Kirk, O., Bannister, W., Mocroft, A., Sabin, C., . . . Lundgren, J. D. (2011). The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 22(4), 516-523. DOI |
| 2011 | Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7. DOI |
| 2011 | Wright, S. T., Carr, A., Woolley, I., Giles, M., Hoy, J., Cooper, D. A., & Law, M. G. (2011). CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(1), 72-79. DOI |
| 2011 | Wilson, D., Grulich, A., & Boyd, M. (2011). Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men. Clinical Infectious Diseases, 53(6), 611-612. DOI Scopus2 Europe PMC1 |
| 2010 | Martin, A., Amin, J., Cooper, D. A., Carr, A., Kelleher, A. D., Bloch, M., . . . Emery, S. (2010). Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS, 24(17), 2657-2663. DOI |
| 2010 | Zhou, J., Li, P., Kumarasamy, N., Boyd, M., Chen, Y., Sirisanthana, T., . . . Pujari, S. (2010). Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine, 11(1), 31-39. DOI Scopus19 Europe PMC11 |
| 2010 | Carey, D., Amin, J., Boyd, M., Petoumenos, K., & Emery, S. (2010). Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 65(9), 1878-1888. DOI Scopus30 Europe PMC19 |
| 2010 | Boyd, M., & Nwizu, C. (2010). Operational research in HIV priority areas: the African way. The Lancet, 376(9734), 4-6. DOI Scopus1 Europe PMC2 |
| 2010 | Boyd, M., & Hill, A. (2010). Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. PharmacoEconomics, 28(SUPPL. 1), 17-34. DOI Scopus12 Europe PMC2 |
| 2010 | Boyd, M. (2010). Current and future management of treatment failure in low- and middle-income countries. Current Opinion in HIV and AIDS, 5(1), 83-89. DOI Scopus14 Europe PMC9 |
| 2009 | Boyd, M. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194-199. DOI Scopus34 Europe PMC30 |
| 2009 | Byakwaga, H., Murray, J., Petoumenos, K., Kelleher, A., Law, M., Boyd, M., . . . Cooper, D. (2009). Evolution of CD4<sup>+</sup> T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Research and Human Retroviruses, 25(6), 569-576. DOI Scopus4 Europe PMC6 |
| 2009 | Byakwaga, H., Zhou, J., Petoumenos, K., Law, M., Boyd, M., Emery, S., . . . Mallon, P. (2009). Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. HIV Medicine, 10(3), 143-151. DOI Scopus3 Europe PMC2 |
| 2009 | Boyd, M., Emery, S., & Cooper, D. (2009). Antiretroviral roll-out: the problem of second-line therapy. The Lancet, 374(9685), 185-186. DOI Scopus16 Europe PMC13 |
| 2008 | Boyd, M., Truman, M., Hales, G., Anderson, J., Dwyer, D., & Carr, A. (2008). A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antiviral Therapy, 13(3), 449-453. Scopus8 Europe PMC5 |
| 2008 | Colebunders, R., French, M., Oelrichs, R., & Boyd, M. (2008). Editorial introductions. Current Opinion in HIV and AIDS, 3(4), vii-viii. DOI |
| 2008 | Boyd, M., & Pett, S. (2008). HIV fusion inhibitors: A review. Australian Prescriber, 31(3), 66-69. Scopus1 |
| 2008 | Boyd, M., & Byakwaga, H. (2008). Considering the benefits of disease-specific interventions on overall public health. The Lancet Infectious Diseases, 8(5), 278. DOI Scopus1 Europe PMC1 |
| 2008 | Oelrichs, R., & Boyd, M. (2008). Evidence and policy in the globalized response to AIDS. Current Opinion in HIV and AIDS, 3(4), 477-480. DOI |
| 2007 | Cooper, D., Cahn, P., Lewin, S., Kaldor, J., McClure, C., Kort, R., & Boyd, M. (2007). The Sydney Declaration: a call to scale up research. Lancet, 370(9581), 7-8. DOI Scopus13 Europe PMC9 |
| 2007 | Boyd, M. (2007). Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?. Expert Opinion on Pharmacotherapy, 8(7), 957-964. DOI Scopus13 Europe PMC9 |
| 2007 | Kerr, S., Duncombe, C., Avihingsanon, A., Ananworanich, J., Boyd, M., Sopa, B., . . . Ruxrungtham, K. (2007). Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. Journal of the International Association of Physicians in AIDS Care, 6(1), 36-46. DOI Scopus9 Europe PMC6 |
| 2007 | Boyd, M., & Hedger, S. (2007). An unusual cause of severe metabolic acidosis [5]. Medical Journal of Australia, 186(3), 158. |
| 2007 | Boyd, M., & Cooper, D. (2007). Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research. AIDS, 21(SUPPL. 4), S55-S63. DOI Scopus31 Europe PMC27 |
| 2007 | Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., & Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54. DOI Scopus12 Europe PMC9 |
| 2007 | Boyd, M., Menon, P., Graves, S., & Gordon, D. (2007). A febrile illness with generalized papular rash involving the palms and soles. Clinical Infectious Diseases, 44(5), 704-756. DOI |
| 2007 | Snelling, T., Ossowicz, C., & Boyd, M. (2007). Case report: Co-infections in an HIV-infected man from Malawi. American Journal of Tropical Medicine and Hygiene, 76(1), 180-181. |
| 2007 | Autar, R., Boyd, M., Wit, F., Ruxrungtham, K., Sankote, J., Lange, J., . . . Reiss, P. (2007). Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antiviral Therapy, 12(8), 1265-1271. Scopus5 Europe PMC5 |
| 2006 | Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., . . . Reiss, P. (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Journal of Infectious Diseases, 194(5), 642-650. DOI Scopus23 Europe PMC18 |
| 2006 | Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek, M., . . . Miners, J. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics, 16(5), 321-329. DOI Scopus43 Europe PMC23 |
| 2006 | Boyd, M., Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A., Lange, J., . . . Burger, D. (2006). The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. Journal of Antimicrobial Chemotherapy, 57(6), 1161-1167. DOI Scopus18 Europe PMC7 |
| 2006 | Boyd, M., Dixit, N., Siangphoe, U., Buss, N., Salgo, M., Lange, J., . . . Ruxrungtham, K. (2006). Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). Journal of Infectious Diseases, 194(9), 1319-1322. DOI Scopus11 Europe PMC6 |
| 2006 | Boyd, M., Burger, D., Phanuphak, P., & Cooper, D. (2006). Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]. AIDS, 20(7), 1083-1085. DOI Scopus2 Europe PMC2 |
| 2006 | Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., . . . Phanuphak, P. (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232. Scopus14 Europe PMC10 |
| 2006 | Kong, A., Koukourou, A., Boyd, M., & Crowe, G. (2006). Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. Journal of Clinical Neuroscience, 13(9), 955-958. DOI Scopus12 Europe PMC7 |
| 2006 | Boyd, M., & Rogers, W. (2006). Industry and bioethics: What price the relationship? [3]. PLoS Medicine, 3(6), 0933. DOI Scopus1 Europe PMC1 |
| 2006 | Boyd, M., & Reiss, P. (2006). The long-term consequences of antiretroviral therapy: A review. Journal of HIV Therapy, 11(2), 26-35. Scopus14 Europe PMC12 |
| 2006 | Boyd, M., Clezy, K., Lindley, R., & Pearce, R. (2006). Pandemic influenza: Clinical issues. Medical Journal of Australia, 185(10 SUPPL.), S44-S47. Scopus19 Europe PMC11 |
| 2006 | Boyd, M., & Reiss, P. (2006). Erratum: The long-term effects of antiretroviral therapy: A review (Journal of HIV Therapy 11, 2 (28)). Journal of HIV Therapy, 11(3). |
| 2005 | Boyd, M., Mootsikapun, P., Burger, D., Chuenyam, T., Ubolyam, S., Mahanontharit, A., . . . Ruxrungtham, K. (2005). Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral Therapy, 10(2), 301-307. Scopus38 Europe PMC27 |
| 2005 | Boyd, M., Siangphoe, U., Ruxrungtham, K., Duncombe, C., Stek, M., Lange, J., . . . Phanuphak, P. (2005). Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Medicine, 6(6), 410-420. DOI Scopus14 Europe PMC6 |
| 2004 | Ananworanich, J., Cheunyam, T., Teeratakulpisarn, S., Boyd, M., Ruxrungtham, K., Lange, P., . . . Phanuphak, P. (2004). Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet, 364(9428), 101-102. DOI Scopus16 Europe PMC9 |
| 2004 | Law, W., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., Lange, J., . . . Dore, G. (2004). Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS, 18(8), 1169-1177. DOI Scopus121 Europe PMC87 |
| 2004 | Ruxrungtham, K., Boyd, M., Bellibas, S., Zhang, X., Dorr, A., Kolis, S., . . . Patel, I. (2004). Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology, 44(7), 793-802. DOI Scopus23 Europe PMC14 |
| 2003 | Law, W. P., Dore, G. J., Duncombe, C. J., Mahanontharit, A., Boyd, M. A., Ruxrungtham, K., . . . Cooper, D. A. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.. AIDS (London, England), 17(15), 2191-2199. DOI Europe PMC60 |
| 2003 | Law, W., Dore, G., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., . . . Cooper, D. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199. DOI Scopus95 |
| 2003 | Boyd, M., Zhang, X., Dorr, A., Ruxrungtham, K., Kolis, S., Nieforth, K., . . . Patel, I. (2003). Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. Journal of Clinical Pharmacology, 43(12), 1382-1391. DOI Scopus39 Europe PMC26 |
| 2003 | Boyd, M., Aarnoutse, R., Ruxrungtham, K., Stek, M., Van Heeswijk, R., Lange, J., . . . Burger, D. (2003). Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes, 34(2), 134-139. DOI Scopus18 Europe PMC14 |
| 2003 | Burger, D., Boyd, M., Duncombe, C., Felderhof, M., Mahanontharit, A., Ruxrungtham, K., . . . Reiss, P. (2003). Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy, 51(5), 1231-1238. DOI Scopus56 Europe PMC34 |
Book Chapters
Conference Items
| Year | Citation |
|---|---|
| 2016 | Boyd, M. A. (2016). HIV in Myanmar.. Poster session presented at the meeting of 2016 International Congress for Tropical Medicine and Malaria. Brisbane, Queensland, Australia. |
| 2014 | Holt, S., Gracey, D., Mudge, D., Irish, A., Sevastos, J., Walker, R., . . . Boyd, M. (2014). RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL. |
Grants and Funding
Category 1
| 2014 - 2017 | Clinical Development Award clinical support for 4 years | NHMRC | 2014: $404,884 AUD |
| 2013 | Project Grant award support of the SECOND-LINE study | NHMRC | $449,584.40 AUD |
Category 2
| 2014 | Australian Award Fellowship support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) | Australian Commonwealth Government Department of Foreign Affairs & Trade. | $656,888. |
| 2013 | Australian Award Fellowships support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) | AusAID | $698,160.00 |
Category 3
| 2015 | In support of the development of capacity to measure ARV levels in human tissues: | Merck & Co. IISP grant | $20,000 UAD |
| 2015 | Award in support of Faster and smarter identification of at-risk sexually transmitted infection patients via online, mobile and social platforms | auDA foundation | $20,000 AUD |
| 2014 | Award in project support of The association between virological failure and lopinavir plasma drug levels in the SECOND-LINE trial | Gilead Australia Fellowship Research Grants | 2015: $30,000 AUD |
| 2014 | Independent initiative grant support for an analysis of bone turnover, immune activation and inflammatory biomarkers in the SECOND-LINE DXA-substudy, | Grants Merck Global Affairs | 2014: $304,064 AUD |
| 2012 | Award for support of the RATE study | Gilead Australia Fellowship Research Grants | 2013: $20,000 AUD |
| 2012 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2012: $125,000 USD |
| 2012 | Support of the SECOND-LINE study | Merck & Co. | $1,000,000 USD. |
| 2011 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2011: $125,000 USD |
| 2010 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2010: $125,000 USD |
| 2009 | Support of the SECOND-LINE study | Abbott Inc. | $600,000 AUD |
| 2009 | Support of the SECOND-LINE study | Merck & Co. | 2009: $1,100,000 USD |
| 2008 | Support of the Encore program | Bill and Melinda Gates Foundation | $12,416,901 USD |
Board Memberships
| Date | Role | Board name | Institution name | Country |
|---|---|---|---|---|
| 2015 - ongoing | Member | , Scientific and Program Committee of the Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Conference 2016 | Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) | — |
Committee Memberships
| Date | Role | Committee | Institution | Country |
|---|---|---|---|---|
| 2015 - ongoing | Chair | ASHM International Advisory Group | — | — |
| 2014 - ongoing | Member | Australian National HIV Pre-Exposure Prophylaxis (PrEP) Guidance Committee | — | — |
| 2014 - ongoing | Chair | RACP Working Group | — | — |
| 2014 - ongoing | President | Australasian Society for HIV Medicine (ASHM) | — | — |
| 2014 - ongoing | Chair | Gilead ‘HIV and the Body’ educational meeting faculty | — | — |
| 2013 - ongoing | Chair | Lyell McEwin Hospital, Discipline of Medicine, School of Medicine | University of Adelaide | — |
| 2013 - ongoing | Member | NEAT-id (European Treatment Network for HIV, Hepatitis and Global Infectious Diseases) | — | — |
| 2013 - ongoing | Member | Australasian Society for HIV Medicine (ASHM) Clinical Guidance Committee | — | — |
| 2013 - ongoing | Chair | National Program Theme B Committee for the ASHM 2013 National Conference | — | — |
| 2012 - ongoing | Member | Kirby Institute Higher Degree Committee and Annual Post-Graduate Progress Review academic staff | — | — |
| 2012 - ongoing | Member | ASID Prosthetic Joint Infection Trial Steering Committee | — | — |
| 2012 - ongoing | Member | ASHM NSW HIV Shared Care Workshop Committee | — | — |
| 2012 - ongoing | Member | Australian Society for Infectious Disease (ASID) Native Joint Infection Trial Steering Committee | — | — |
| 2011 - 2014 | Vice-President | Australasian Society for HIV Medicine (ASHM) | — | — |
| 2010 - ongoing | Member | Australian HIV Observational Database (AHOD) Steering Committee | — | — |
| 2009 - ongoing | Vice-President | Australasian Society for HIV Medicine | — | — |
| 2009 - ongoing | Member | ASHM Risk Management and Audit Sub-Committee | — | — |
| 2005 - 2009 | Board Member | Australasian Society for HIV Medicine | — | — |
| 2005 - ongoing | Board Member | Australasian Society for HIV Medicine (ASHM) | — | — |
| 1999 - 2005 | Member | Australasian Society for HIV Medicine | — | — |
Consulting/Advisories
| Date | Institution | Department | Organisation Type | Country |
|---|---|---|---|---|
| 2014 - ongoing | International Advisory Board, Lancet HIV | — | — | — |
| 2014 - ongoing | Merck Australian HIV Advisory Board | — | — | — |
| 2013 - ongoing | ASHM NSW Expert Advisory Committee | — | — | — |
| 2013 - ongoing | Gilead Sciences International HIV Advisory Board | — | — | — |
Editorial Boards
| Date | Role | Editorial Board Name | Institution | Country |
|---|---|---|---|---|
| 2015 - ongoing | Editor-In-chief | AIDS Research & Therapy BMC open access journal | — | — |
Industry Partnerships
| Date | Engagement Type | Partner Name |
|---|---|---|
| 2014 - 2016 | Consultant | Honorary Consultant in HIV Medicine, The Albion Centre |
| 2013 - ongoing | Consultant | HIV and Infectious Diseases Specialist Consultant, Holdsworth House Medical Practice |
Position
Chailr of Medicine
Phone
0881829653
Building
Lyell McEwin Hospital
Org Unit
Medicine